Inovio Pharmaceuticals Inc banner

Inovio Pharmaceuticals Inc
NASDAQ:INO

Watchlist Manager
Inovio Pharmaceuticals Inc Logo
Inovio Pharmaceuticals Inc
NASDAQ:INO
Watchlist
Price: 1.63 USD -1.81%
Market Cap: $112.6m

Balance Sheet

Balance Sheet Decomposition
Inovio Pharmaceuticals Inc

Balance Sheet
Inovio Pharmaceuticals Inc

Rotate your device to view
Balance Sheet
Currency: USD
Dec-2002 Dec-2003 Dec-2004 Dec-2005 Dec-2006 Dec-2007 Dec-2008 Dec-2009 Dec-2010 Dec-2011 Dec-2012 Dec-2013 Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023 Dec-2024 Dec-2025
Assets
Cash & Cash Equivalents
1
13
18
17
8
10
14
30
20
17
6
34
41
58
19
24
24
22
251
71
46
14
66
44
Cash Equivalents
1
13
18
17
8
10
14
30
20
17
6
34
41
58
19
24
24
22
251
71
46
14
66
44
Short-Term Investments
0
0
0
0
15
17
0
10
2
13
8
19
53
105
86
104
58
67
161
330
207
131
28
14
Total Receivables
0
0
0
0
0
1
1
0
0
1
1
3
3
7
17
6
4
2
19
8
12
2
1
0
Accounts Receivables
0
0
0
0
0
1
1
0
0
0
1
3
3
7
16
6
3
1
19
5
2
0
1
0
Other Receivables
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
1
1
1
3
10
2
0
0
Other Current Assets
2
0
0
1
1
1
0
4
1
1
1
3
3
2
3
4
3
3
40
39
51
5
3
3
Total Current Assets
3
14
18
18
24
29
15
45
23
32
16
59
99
172
125
138
88
94
471
448
315
153
98
61
PP&E Net
0
0
0
0
0
0
0
0
0
0
0
3
5
7
9
18
16
27
24
29
18
14
12
9
PP&E Gross
0
0
0
0
0
0
0
0
0
0
0
0
5
7
9
18
16
27
24
29
18
14
12
9
Accumulated Depreciation
2
2
2
2
2
2
1
2
2
2
2
0
3
4
5
7
10
13
16
19
22
21
16
17
Intangible Assets
2
2
2
6
7
6
10
13
11
9
7
6
5
4
8
6
5
4
3
3
2
0
0
0
Goodwill
0
0
0
4
4
4
4
10
10
10
10
10
10
10
11
11
11
11
11
11
11
0
0
0
Long-Term Investments
0
0
0
0
0
0
9
12
11
9
11
10
12
20
20
11
9
6
5
4
2
3
2
2
Other Long-Term Assets
0
0
0
0
0
0
0
0
0
0
1
1
1
1
2
3
3
3
26
1
1
1
2
2
Other Assets
0
0
0
4
4
4
4
10
10
10
10
10
10
10
11
11
11
11
11
11
11
0
0
0
Total Assets
5
N/A
16
+200%
21
+29%
29
+38%
36
+24%
40
+11%
39
-2%
81
+107%
56
-30%
61
+9%
45
-26%
88
+96%
132
+49%
214
+62%
174
-19%
187
+8%
131
-30%
144
+10%
540
+275%
496
-8%
349
-30%
171
-51%
113
-34%
74
-34%
Liabilities
Accounts Payable
1
1
2
2
2
2
0
4
2
1
1
6
3
9
14
16
15
8
1
25
65
5
6
3
Accrued Liabilities
0
0
2
1
1
1
1
0
3
4
4
1
5
7
13
17
15
17
33
36
29
21
16
12
Short-Term Debt
0
0
0
0
0
0
12
12
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Current Portion of Long-Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17
0
0
Other Current Liabilities
1
0
1
1
4
1
1
3
1
6
4
22
6
16
17
3
6
7
8
5
3
0
13
29
Total Current Liabilities
2
1
5
4
7
3
15
19
6
11
8
29
14
31
44
35
35
32
42
66
97
43
35
44
Long-Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
77
19
15
17
0
0
0
Deferred Income Tax
0
0
0
1
1
1
1
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
Minority Interest
0
0
0
0
5
0
0
1
1
1
1
0
0
0
0
0
0
2
0
0
0
0
0
0
Other Liabilities
0
0
0
1
5
4
4
0
2
2
2
6
6
6
6
9
9
30
18
16
13
11
9
7
Total Liabilities
2
N/A
1
-30%
5
+357%
6
+2%
18
+223%
9
-51%
20
+127%
20
+1%
10
-52%
14
+44%
11
-22%
36
+232%
21
-43%
38
+86%
50
+32%
45
-11%
44
-1%
141
+218%
79
-44%
96
+22%
126
+31%
54
-58%
45
-17%
50
+12%
Equity
Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Retained Earnings
53
76
88
114
129
140
153
177
195
210
230
296
332
361
435
523
620
740
906
1 210
1 488
1 623
1 730
1 815
Additional Paid In Capital
57
91
103
138
147
171
172
238
241
257
264
348
443
534
557
666
708
743
1 367
1 610
1 711
1 741
1 799
1 840
Other Equity
0
0
0
0
0
0
0
0
0
0
0
0
0
3
1
0
1
0
0
0
1
1
1
1
Total Equity
4
N/A
15
+304%
16
+3%
23
+51%
18
-23%
31
+71%
19
-38%
61
+217%
47
-23%
47
+2%
34
-27%
52
+53%
111
+112%
176
+58%
123
-30%
142
+16%
87
-39%
3
-96%
461
+13 325%
400
-13%
222
-44%
117
-47%
69
-42%
24
-65%
Total Liabilities & Equity
5
N/A
16
+199%
21
+29%
29
+38%
36
+24%
40
+11%
39
-2%
81
+107%
56
-30%
61
+9%
45
-26%
88
+96%
132
+49%
214
+62%
174
-19%
187
+8%
131
-30%
144
+10%
540
+275%
496
-8%
349
-30%
171
-51%
113
-34%
74
-34%
Shares Outstanding
Common Shares Outstanding
0
0
0
1
1
1
1
2
2
3
3
5
5
6
6
8
8
8
16
18
21
23
36
69
Preferred Shares Outstanding
0
0
0
2
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett